Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sovaprevir + Odalasvir + Ribavirin in HCV GT-1
NCT01849562Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2013
- Primary completion
- Nov 2013
- Modality
- Small Molecules, Modified Peptides
01
Overview
Phase 2, randomised, double-blind trial of sovaprevir and odalasvir in hepatitis C (HCV) (3 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Sustained Virologic Response 4 Weeks After Treatment and Safety and Tolerability of Sovaprevir and ACH-3102 in Combination with RBV at 12 weeks. Started Apr 2013; status: completed.
02
Drugs
sovaprevirodalasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01849562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01849562.